Overcoming Late-Stage Hepatic (Liver) Cancer with Advanced Treatment Options
For the last 20 years, patients diagnosed with early and late-stage liver
cancer have turned to
Envita Medical Centers, an integrative center of excellence for personalized
oncology, to
receive a personalized
and genetically driven approach to care that we believe gives our patients a
greater chance to achieve positive outcomes. We have achieved success by
combining years of collective research and clinical experience treating the
most difficult and complex cancer diagnoses by utilizing powerful targeted
personalized treatments. We often hear from our patients, that they wish they
had found us sooner. We feel that speaks volumes to the type of precision care
patients should be receiving.
Envita Medical Centers doesn't make any guarantee of outcomes.
Results are not typical and will vary from person to person and
should not be expected.
Liver cancer is one of the most
common cancers
worldwide and despite the many advancements in prevention, screening,
diagnostics, and treatment; incidences and deaths from primary liver cancer
continue to climb in the standardized treatment model [1] [2]. Unfortunately,
standard hepatic cancer treatment protocols are estimated to be curative in
less than 20% of primary liver cancer patients [3]. Most patients only receive
palliative treatment meant to optimize quality of life and mitigate suffering
[3]. Standardized oncology focuses on management of symptoms, as opposed to
achieving remission, because conventional radiotherapy and chemotherapy are
often ineffective long term with liver cancers [3]. Especially late-stage
liver cancers that have metastasized add multiple other complications to
treatment.
Patients deserve a
precision approach
that better accounts for the individuals’ unique tumor biology targets and
immunotherapy targets to come against cancer’s progression in far more
detailed and comprehensive manner. With nearly two decades of clinical
experience, Envita Medical Centers has been able to overcome many of the
challenges associated with hepatic cancer treatment planning. By providing
customizable advanced integrative treatment options and procedures that go
beyond the standardized options, Envita has been able to out preform many
renowned cancer treatment centers.
Understanding and Fighting the Cause of Hepatocellular Carcinoma (HCC)
The most common primary liver cancer is Hepatocellular carcinoma (HCC).
Patients suffering from HCC only have access to suboptimal care in the
conventional medical system [4]. This is unfortunate because HCC is on the
rise worldwide [4] and in the United States alone, an estimated 42,000 adults
were diagnosed with primary liver cancer in 2020 [5].
Treating
the root causes of cancer
is a key focus at Envita. We have seen clinically that addressing the
causative factors, in combination with our precision treatment modalities,
gives our patients the best possible chance to maintain lasting results
against their disease. If the cause of the cancer is not properly addressed,
then the likelihood of recurrence is much higher. Hepatitis, for instance, is
a major risk factor for developing HCC. More than 70% of HCC cases worldwide
are correlated with chronic hepatitis B and C [1].
Without comprehension of the mechanisms that may have led to the development
of the cancer, other cancer treatment facilities may not possess the expertise
to understand and effectively treat the chronic conditions that may be feeding
the cancer’s continued growth and spread. Fortunately, at Envita, we
specialize in treating complex late-stage cancers in addition to chronic
infections. We have developed proprietary technology and clinical expertise
that gives us a decided edge in understanding and treating Hepatocellular
carcinoma caused by chronic infections.
Envita Medical Centers doesn't make any guarantee of outcomes.
Results are not typical and will vary from person to person and
should not be expected.
Envita is extremely experienced in identifying and treating the infectious
causes of cancer. We have performed and continue to carry out extensive
research into the topic and have even published on the various correlations
between
infectious diseases and cancer. Our
dedication to research shows how uniquely qualified and experienced
Envita is at treating not only
late-stage
progressive cancer, but also
chronic infections
and the complex
connection
between the two. Viruses like hepatitis can affect the genes in a cell as well as
potentially deregulate tumor suppression and oncogene expression [3]. In
addition, hepatitis facilitates pro-inflammatory cytokines that creates a
perfect environment for caner growth [3]. By incorporating inflammatory
marker, oncogene downregulation, tumor suppressor gene upregulation, and
immunotherapy; Envita
provides a comprehensive approach that accounts for the multiple
variables that combine to form each patient’s unique cancer blueprint. It is
not enough to treat liver cancer alone, being able to effectively combat the
chronic infections and any other mitigating cancer-causing factors is pivotal
for providing a comprehensive cancer treatment.
Envita Medical Centers doesn't make any guarantee of outcomes.
Results are not typical and will vary from person to person and
should not be expected.
CIPI™ Treatment for Liver Cancer
CIPI™, or Chemo Immunotherapy Percutaneous Injections, is a proprietary form
of tumor embolization that Envita utilizes to treat tumors that may be
inoperable or difficult to penetrate. CIPI™ is extremely useful for treating
liver cancer because it can circumvent factors that traditionally make this
cancer extremely hard to treat. Not only is liver cancer often inoperable, but
liver cancer can form a thick stroma around the tumor that resists penetration
by
normal chemotherapy
methods. Unlike other tumor embolization methods, CIPI™ takes the precision a
step further by directly injecting targeted chemotherapy and adjunctive immune
modulating agents into the tumor through a thin catheter for precision
absorption of the medication directly into the tumor. This method allows
Envita’s custom
medications
to effectively bypass the thick stroma while providing optimal therapeutic
absorption. However, CIPI™ goes beyond tumor embolization and can create a
systemic immune response that works to attack metastasized cancer cells in
addition to destroying solid tumors.
This video is for informational purposes only. Individual results will vary. Envita makes no guarantees.
Consult with
your doctor to see if CIPI™ is right for you. Not every patient is a candidate for Chemo Immunotherapy
Percutaneous Injection. Some cancers may not have actionable biomarkers or molecular profiles. Do not alter
your medical
care based on any information provided in this video. Please, consult your doctor prior to changing or
stopping any
current medical treatment you are receiving.
By utilizing customized protocols of genetically targeted medications, Envita
creates a personalized treatment plan custom designed for each patient's
unique cancer presentation. Envita designs this customized protocol through a
proprietary algorithm that combines information on immune markers, oncogenes,
cancer antigens, and chemosensitivity. With help from the algorithm, Envita’s
experienced doctors choose the precision targeted chemotherapies,
immunotherapies, and natural agents for each individual patient’s specific
needs. During the CIPI™ procedure, these agents are injected directly into the
tumor through the arterial blood supply to contain and focus the agents on the
tumor itself. These agents go to work embolizing the solid tumor over multiple
treatments.
From there, CIPI™ works by involving the immune system to fight metastasized
cancer cells throughout the body as well. After the tumor is embolized by the
CIPI™ treatment, antigens from the destroyed tumor can be used by the body to
target free floating cancer cells. The systemic immune response caused by the
CIPI procedure is an important factor that helps treat beyond the solid tumor
causing an immune cascade throughout the body. The majority of the patients we
see at Envita are diagnosed with a late-stage form of liver cancer and
treating the solid tumor alone is not going to be enough to address their
complete disease. CIPI™ allows us to treat the hard to reach solid tumors
while also addressing the metastasized free-floating cancer cells in the body.
The goal with CIPI™ is not just to kill the tumor but to comprehensively treat
cancer wherever it may spread.
Envita Specializes in Late Stage Cancer Treatment
Hepatocellular carcinoma, and other liver cancers, cause symptoms like weight
loss, loss of appetite, and fatigue; because these symptoms are so vague and
broad many liver cancer patients are not diagnosed until the disease has
progressed and the prognosis has become unfavorable. Envita Medical Centers
specializes in treating late-stage and complex cancers; our clinical
experience has shown us that a personalized treatment protocol is even more
important in the later stages of cancer. Cancer is a genetic disease that
differs wildly from patient to patient. With the conventional approach, these
unique differences are not accounted for; and cancer is treated based on type
and stage instead of your unique epigenetics and
cancer
biomarkers. Furthermore, the standard approach of cancer treatment utilizes maximum
allowable doses of chemotherapy that has the potential to destroy a patient’s
immune system, when not targeted properly, which can lead to further
progression of disease. Through a form of micro-dosed
genetically targeted
chemotherapy
and advanced immunotherapies, Envita Medical Centers provides a completely
customized treatment protocol that comprehensively builds the immune system
and attacks the cancer to create a multifaceted approach. The immune system is
the first line of defense against cancer and is one of the greatest weapons
for cancer treatment. Conventional medicine largely ignores the immune systems
importance and untargeted chemotherapy can further deteriorate the patient’s
immune system. By restoring the immune system first and foremost, Envita
activates one of the greatest weapons against cancer and improves the
viability of further treatment.
While some patients may find success with conventional treatment methods, the
vast majority of patients we treat at Envita have already exhausted the
traditional methods and are looking for a more advanced precision-based
approach. Our clinical experience with liver cancer and other inoperable
tumors has led to the development of specialized treatment options and
procedures that we find to potentially be beneficial for our patient base.
Envita offers a synergetic approach that combines superior genetic targeting,
proprietary CIPI™ delivery, and advanced immunotherapies that no other clinic
in the world can offer. Contact one of our patient care educators today, to
see if we can improve your cancer treatment plan. We are looking forward to
hearing from you, and we wish you the best of health!
References
[1] Knawy, B.A., L. Bolondi, and K.R. Reddy, Hepatocellular Carcinoma : A
Practical Approach. 2009, Baton Rouge, UNITED STATES: CRC Press LLC.
[2] Balogh, J., et al., Hepatocellular carcinoma: a review. Journal of
hepatocellular carcinoma, 2016. 3: p. 41-53.
[3] Qiao, L., Y. Li, and X. Yan, Molecular Aspects of Hepatocellular
Carcinoma. 2012: Bentham Science Publishers.
[4] Williams, R., S.D. Taylor-Robinson, and S.D. Taylor-Robinson, Clinical
Dilemmas in Primary Liver Cancer. 2011, Hoboken, UNITED KINGDOM: John Wiley
& Sons, Incorporated.
[5] American Cancer Society. Key Statistics About Liver Cancer. 2020;
Available from:
https://www.cancer.org/cancer/liver-cancer/about/what-is-key-statistics.html.
Recommended Videos
4 Essential Targets to Powerful Cancer Treatment
Advanced Genetic Testing to Uncover Critical Cance...
